NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 October 2011 A systematic review has found that clinic and home blood pressure (BP) measurement have insufficient accuracy to be used as a single diagnostic test and may […]
Category Archives: Cardiovascular disease
NPC Archive Item: EMA recommends restricting the use of dronedarone▼
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 29 September 2011 Following a review of its benefit-risk balance, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that dronedarone▼ should only […]
NPC Archive Item: What is the optimal duration of anticoagulant therapy following VTE?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25th August 2011 A pooled analysis of data from seven randomised controlled trials (RCTs) suggests that three months of anticoagulant treatment is generally sufficient following a venous thromboembolism (VTE) […]
NPC Archive Item: New NICE guidance on management of stable angina
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The NICE Centre for Clinical Practice is an NHS Evidence accredited provider 19 August 2011 New NICE guidance on the management of stable angina (clinical guideline [CG] 126) has […]
NPC Archive Item: A2RAs: no substantially increased risk of MI, but ACE inhibitors still first line
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28 June 2011 A large meta-analysis provides evidence that angiotensin-II receptor antagonists (A2RAs) do not substantially increase the risk of MI, all-cause or CV mortality, or angina, as was […]
NPC Archive Item: Olmesartan reduces disease oriented outcomes but may have potential cardiovascular safety concerns
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28th March 2011 The ROADMAP trial found olmesartan delayed the onset of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. While this disease-oriented outcome (DOO) suggested a potential benefit […]
NPC Archive Item: More improvement needed in the drug management of heart failure
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 8th February 2011 The National Heart Failure audit 2010 confirms the improvements suggested last year in the use of key treatments for heart failure, such as ACE inhibitors and beta […]
NPC Archive Item: Does eplerenone▼ have a role in mild heart failure?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 13th January 2011 The EMPHASIS-HF study found that adding eplerenone▼ to recommended therapy for heart failure (HF) with left ventricular systolic dysfunction (LVSD) reduced the risk of a composite […]
NPC Archive Item: New from NICE: Important changes in the use of clopidogrel and modified-release dipyridamole
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 17 May 2011 Clopidogrel* alone is now recommended by NICE with no limits on duration of treatment in people who have had an ischaemic stroke. Modified-release (MR) dipyridamole plus aspirin […]
NPC Archive Item: Reducing treatment dose errors with low molecular weight heparins
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 06 September 2010 Introduction In July 2010, the National Patient Safety Agency (NPSA) issued its Rapid Response Report: Reducing treatment dose errors with low molecular weight heparins (LMWHs)1, making […]